Survival of macroencapsulated allogeneic parathyroid tissue one year after transplantation in nonimmunosuppressed humans.
The use of immunoisolation devices may allow transplantation without need for immunosuppression and could widen the indications for cell transplantation. In this study, we evaluated the survival of encapsulated parathyroid tissue in nonimmunosuppressed humans. Autologous parathyroid implants: Seven patients undergoing parathyroidectomy had devices containing small pieces of their own parathyroid tissue implanted SC. These devices were explanted after 2-4 weeks for histological evaluation. Allogeneic parathyroid implants: Four patients with chronic hypoparathyroidism were transplanted with one to three large (40 microl) and one small (4.5 microl) device filled with meshed parathyroid tissue and implanted SC. The small devices were explanted at 4 weeks, while the large ones were explanted 8.5 to 14 months after implantation. In both studies, control implants were placed in nude mice. Autologous study results: At explantation, the grafts consisted of 22 +/- 6% endocrine tissue and 63 +/- 7% fibrosis, while 15 +/- 5% of the grafts were necrotic. Allogeneic study results: In devices explanted from the patients at 4 weeks, fibrosis dominated and only 1%, 5%, and 23% of the grafts consisted of endocrine tissue. A similar histological appearance was found in grafts from nude mice. In devices explanted at 8.5-14 months, histologically intact endocrine tissue was found in all patients. However, nearly all the tissue consisted of fibrosis. There was no detectable increase in the parathormone (PTH) level in all patients. Macroencapsulated human allogeneic parathyroid tissue can survive up to 1 year after transplantation into nonimmunosuppressed patients. However, marked fibroblast overgrowth occurred, especially in the allogeneic implant study, using meshed parathyroid tissue. This was probably not related to the allo-response, because similar findings were observed in the nude mouse implants. In future studies, better tissue preparation and improvements in the physiological milieu inside the device may help to reduce fibroblast overgrowth and increase survival of the parathyroid cells.
Tibell
A
A
Department of Transplantation Surgery, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden. Annika.Tibell@karo.ki.se
Rafael
E
E
Wennberg
L
L
Nordenström
J
J
Bergström
M
M
Geller
R L
RL
Loudovaris
T
T
Johnson
R C
RC
Brauker
J H
JH
Neuenfeldt
S
S
Wernerson
A
A
D000818:Animals; D001132:Arm; D002214:Capsules; D017690:Cell Transplantation / Q000379:methods*; D005355:Fibrosis; D006085:Graft Survival; D006801:Humans; D007121:Immunocompetence; D007165:Immunosuppression Therapy; D051379:Mice; D008819:Mice, Nude; D009336:Necrosis; D010280:Parathyroid Glands / Q000637:transplantation*; D016105:Parathyroidectomy; D014182:Transplantation, Autologous
D002214:Capsules